PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29177329-4	2017	FDPP-TPA nanoparticles (NPs) obtained by re-precipitation exhibit a high molar extinction coefficient (epsilon = 2.13 (+-0.2) x 104 M-1 cm-1), excellent photothermal conversion efficiency (eta = 47%) and favorable singlet oxygen quantum yield (PhiDelta(X) = 40%).	Tetradecanoylphorbol Acetate	5-8	endothelin receptor type A	Homo sapiens	189-192	
26785427-4	2016	On the basis of a tiny chemical modification in TPA-BZP, a green-light donor-acceptor molecule, we designed and synthesized CzP-BZP with this efficeient combination of high PL efficiency of eta(PL) = 75% in the solid state and maximal exciton utilization efficiency up to 48% (especially, the internal quantum efficiency of eta(IQE) = 35% substantially exceed 25% of spin statistics limit) in OLED.	Tetradecanoylphorbol Acetate	48-51	endothelin receptor type A	Homo sapiens	190-193	
26785427-4	2016	On the basis of a tiny chemical modification in TPA-BZP, a green-light donor-acceptor molecule, we designed and synthesized CzP-BZP with this efficeient combination of high PL efficiency of eta(PL) = 75% in the solid state and maximal exciton utilization efficiency up to 48% (especially, the internal quantum efficiency of eta(IQE) = 35% substantially exceed 25% of spin statistics limit) in OLED.	Tetradecanoylphorbol Acetate	48-51	endothelin receptor type A	Homo sapiens	324-327	
17034213-8	2006	The organic light-emitting diodes (OLEDs) with OXD and TPA showed green emission with electroluminescence (EL) quantum efficiencies of eta(EL) approximately 10(-2)%, while very weak EL efficiency of eta(EL) approximately 10(-5)% was observed with PYR.	Tetradecanoylphorbol Acetate	55-58	endothelin receptor type A	Homo sapiens	135-138	
17034213-8	2006	The organic light-emitting diodes (OLEDs) with OXD and TPA showed green emission with electroluminescence (EL) quantum efficiencies of eta(EL) approximately 10(-2)%, while very weak EL efficiency of eta(EL) approximately 10(-5)% was observed with PYR.	Tetradecanoylphorbol Acetate	55-58	endothelin receptor type A	Homo sapiens	199-202	
10636851-10	2000	Synergistic promoter activation (>/=100-fold) is observed when PKCepsilon- or -eta-transfected cells are treated with TPA.	Tetradecanoylphorbol Acetate	121-124	endothelin receptor type A	Homo sapiens	82-85	
8618024-5	1996	The activity of the eta isoform also remained unchanged after the 12-O-tetradecanoyl-phorbol-13-acetate treatment, as judged by binding ATP analog, autophosphorylation, and phosphorylation of an exogenous substrate.	Tetradecanoylphorbol Acetate	66-103	endothelin receptor type A	Homo sapiens	20-23	
9506439-7	1998	Transfection of the CAT-involucrin promoter expression vector with PKC-alpha or PKC-eta expression vectors resulted in a significant increase in the TPA-dependent involucrin promoter activity.	Tetradecanoylphorbol Acetate	149-152	endothelin receptor type A	Homo sapiens	84-87	
9506439-14	1998	Gel retardation analyses disclosed that TPA stimulated the specific DNA binding of the nuclear protein(s) of control, PKC-alpha, or PKC-eta-transfected SVHK cells, but not of PKC-gamma-transfected cells.	Tetradecanoylphorbol Acetate	40-43	endothelin receptor type A	Homo sapiens	5-8	
9506439-16	1998	These results indicate that PKC, specifically PKC-alpha and PKC-eta, mediates the TPA-dependent activation of involucrin gene expression of SVHK cells.	Tetradecanoylphorbol Acetate	82-85	endothelin receptor type A	Homo sapiens	64-67	
9176109-6	1997	Using immunocytochemistry, PKC theta, delta and eta had distinct patterns of redistribution following activation by phorbol myristate acetate (PMA).	Tetradecanoylphorbol Acetate	116-141	endothelin receptor type A	Homo sapiens	33-36	
9176109-6	1997	Using immunocytochemistry, PKC theta, delta and eta had distinct patterns of redistribution following activation by phorbol myristate acetate (PMA).	Tetradecanoylphorbol Acetate	143-146	endothelin receptor type A	Homo sapiens	33-36	
8757771-8	1996	Moreover, for two of these isozymes (betaII and eta), the localization differs after phorbol 12-myristate 13-acetate treatment as compared with collagen treatment.	Tetradecanoylphorbol Acetate	85-116	endothelin receptor type A	Homo sapiens	38-41